Via ESGREV: COVID-19 FAQ document

The ESCMID Study Group for Respiratory viruses (ESGREV) has collected a panel of experts to answer some of the frequently asked questions surrounding the various COVID-19 vaccines to better guide vaccine prescribers, administrators, and recipients. This guide will be periodically updated when new data becomes available. 

The document covers types and availability of different vaccines, immunity, safety, considerations for specific patient populations, and general considerations spanning the 29 questions addressed. Read it here.

› Read more

ECCMID Slam Poetry Workshops - sign up today!

For ECCMID 2021, we are happy to be hosting 4 slam poetry workshops, one on each day of ECCMID, where participants can meet up in the company of a slam poet to express their life experiences during the COVID-19 Pandemic through the medium of slam poetry.

Slam poetry is an exciting artform that brings the classic expressiveness of poetry into a less-structured and more accessible package!

It could be about what has been happening in your hospital, at home or even online – whatever it is, we want to hear you slam about it!

A valid ECCMID registration is required in order to register for the workshop.

› Read more

ESCMID Vlogs: New thoughts from the community!

Be sure to check out the new ESCMID Vlogs, with new videos being added every week!

Recently added are thoughts from ESCMID Professional Affairs Officer, Emmanuelle Cambau, looking forward to an online ECCMID!

Visit the Vlog playlist on the ESCMID YouTube Channel to watch these vlogs and many others!

› Read more

GARDP Live Webinar: New clinical trial designs for evaluation of antimicrobial agents

Don’t miss the next GARDP Live Webinar ‘New clinical trial designs for evaluation of antimicrobial agents’, taking place on Thursday, 27 May 2021 from 09:30 – 11:00 CEST.

Speaking in the webinar are two Australian colleagues, David Paterson (Director, University of Queensland Centre for Clinical Research) and Julie Marsh (Biostatistical Lead, Wesfarmers Centre of Vaccines and Infectious Diseases, University of Western Australia).

Register on the GARDP website.

› Read more

CMI highlight: Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis

The aim of this study was to develop and validate a Pseudomonas aeruginosa genotypic resistance score, based on the analysis of the whole genome sequence resistome, to predict antimicrobial susceptibility phenotypes.

The analysis of the 100 wildtype isolates yielded a catalogue of 455 natural polymorphisms in the 40 genes involved in mutational resistance. However, resistance mutations and high-risk clones (such as ST235) were also documented among a few wildtype isolates. Overall, the capacity of the genotypic score (<0.5) for predicting phenotypic susceptibility (S+I in the case of meropenem) was very high (95-100%). In contrast, the capacity of the genotypic score to predict resistance (≥1) was far more variable depending on the agent. Prediction of meropenem clinical resistance was particularly low (18/39, 46.1%), whereas it classified clinical ceftolozane/tazobactam resistance in 100% (7/7) of cases.

› Read more